Cecilia Boccalini, Debora Elisa Peretti, Gregory Mathoux, Leonardo Iaccarino, Federica Ribaldi, Max Scheffler, Daniela Perani, Giovanni B. Frisoni, Valentina Garibotto
{"title":"早期18F-Flortaucipir tau-PET作为阿尔茨海默病脑代谢的代理：与18F-FDG-PET和早期淀粉样蛋白pet的比较","authors":"Cecilia Boccalini, Debora Elisa Peretti, Gregory Mathoux, Leonardo Iaccarino, Federica Ribaldi, Max Scheffler, Daniela Perani, Giovanni B. Frisoni, Valentina Garibotto","doi":"10.1007/s00259-024-07063-4","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>As dual-phase amyloid-PET can evaluate amyloid (A) and neurodegeneration (N) with a single tracer injection, dual-phase tau-PET might be able to provide both tau (T) and N. Our study aims to assess the association of early-phase tau-PET scans and <sup>18</sup>F-fluorodeoxyglucose (FDG) PET and their comparability in discriminating Alzheimer’s disease (AD) patients and differentiating neurodegenerative patterns.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>58 subjects evaluated at the Geneva Memory Center underwent dual-phase <sup>18</sup>F-Flortaucipir-PET with early-phase acquisition (eTAU) and <sup>18</sup>F-FDG-PET within 1 year. A subsample of 36 participants also underwent dual-phase amyloid-PET (eAMY). Standardized uptake value ratios (SUVRs) were calculated to assess the correlation of eTAU and their respective <sup>18</sup>F-FDG-PET and eAMY scans. Hypometabolism and hypoperfusion maps and their spatial overlap were also evaluated at the individual level visually and semiquantitatively. Receiver operating characteristic analyses were performed to compare the discriminative power of eTAU, FDG, and eAMY SUVR between A-/T- and A+/T + participants.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Strong positive correlations were found between eTAU and FDG SUVRs (<i>r</i> = 0.84, <i>p</i> < 0.001) and eTAU and eAMY SUVRs (<i>r</i> > 0.87, <i>p</i> < 0.001). Clusters of significant hypoperfusion with good correspondence to hypometabolism topographies were found at the individual level, independently of the underlying neurodegenerative patterns. Both eTAU and FDG SUVRs significantly distinguished A+/T + from A-/T- individuals (AUC<sub>eTAU</sub>=0.604, AUC<sub>FDG</sub>=0.748) with FDG performing better than eTAU (<i>p</i> = 0.04). eAMY and eTAU SUVR showed comparable discriminative power.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Early-phase <sup>18</sup>F-Flortaucipir-PET can provide perfusion information closely related to brain regional glucose metabolism and perfusion measured by early-phase amyloid-PET, even if less accurate than FDG-PET as a biomarker for neurodegeneration.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"120 1","pages":""},"PeriodicalIF":7.6000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Early-phase 18F-Flortaucipir tau-PET as a proxy of brain metabolism in Alzheimer’s disease: a comparison with 18F-FDG-PET and early-phase amyloid-PET\",\"authors\":\"Cecilia Boccalini, Debora Elisa Peretti, Gregory Mathoux, Leonardo Iaccarino, Federica Ribaldi, Max Scheffler, Daniela Perani, Giovanni B. Frisoni, Valentina Garibotto\",\"doi\":\"10.1007/s00259-024-07063-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Purpose</h3><p>As dual-phase amyloid-PET can evaluate amyloid (A) and neurodegeneration (N) with a single tracer injection, dual-phase tau-PET might be able to provide both tau (T) and N. Our study aims to assess the association of early-phase tau-PET scans and <sup>18</sup>F-fluorodeoxyglucose (FDG) PET and their comparability in discriminating Alzheimer’s disease (AD) patients and differentiating neurodegenerative patterns.</p><h3 data-test=\\\"abstract-sub-heading\\\">Methods</h3><p>58 subjects evaluated at the Geneva Memory Center underwent dual-phase <sup>18</sup>F-Flortaucipir-PET with early-phase acquisition (eTAU) and <sup>18</sup>F-FDG-PET within 1 year. A subsample of 36 participants also underwent dual-phase amyloid-PET (eAMY). Standardized uptake value ratios (SUVRs) were calculated to assess the correlation of eTAU and their respective <sup>18</sup>F-FDG-PET and eAMY scans. Hypometabolism and hypoperfusion maps and their spatial overlap were also evaluated at the individual level visually and semiquantitatively. Receiver operating characteristic analyses were performed to compare the discriminative power of eTAU, FDG, and eAMY SUVR between A-/T- and A+/T + participants.</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>Strong positive correlations were found between eTAU and FDG SUVRs (<i>r</i> = 0.84, <i>p</i> < 0.001) and eTAU and eAMY SUVRs (<i>r</i> > 0.87, <i>p</i> < 0.001). Clusters of significant hypoperfusion with good correspondence to hypometabolism topographies were found at the individual level, independently of the underlying neurodegenerative patterns. Both eTAU and FDG SUVRs significantly distinguished A+/T + from A-/T- individuals (AUC<sub>eTAU</sub>=0.604, AUC<sub>FDG</sub>=0.748) with FDG performing better than eTAU (<i>p</i> = 0.04). eAMY and eTAU SUVR showed comparable discriminative power.</p><h3 data-test=\\\"abstract-sub-heading\\\">Conclusion</h3><p>Early-phase <sup>18</sup>F-Flortaucipir-PET can provide perfusion information closely related to brain regional glucose metabolism and perfusion measured by early-phase amyloid-PET, even if less accurate than FDG-PET as a biomarker for neurodegeneration.</p>\",\"PeriodicalId\":11909,\"journal\":{\"name\":\"European Journal of Nuclear Medicine and Molecular Imaging\",\"volume\":\"120 1\",\"pages\":\"\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-01-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Nuclear Medicine and Molecular Imaging\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00259-024-07063-4\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-024-07063-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
摘要
目的：通过单次示踪剂注射，双相tau-PET可以评估淀粉样蛋白(A)和神经变性(N)，双相tau-PET可能同时提供tau (T)和N。我们的研究旨在评估早期tau-PET扫描与18f -氟脱氧葡萄糖（FDG） PET的相关性及其在区分阿尔茨海默病（AD）患者和区分神经变性模式方面的可比性。方法58例在日内瓦记忆中心接受了两期18f - flortauciir - pet早期获得（eTAU）和18F-FDG-PET。36名参与者的子样本也接受了双期淀粉样蛋白pet （eAMY）。计算标准化摄取值比（SUVRs）以评估eTAU与其各自的18F-FDG-PET和eAMY扫描的相关性。低代谢和低灌注图及其空间重叠也在个体水平上进行了视觉和半定量评估。进行受试者工作特征分析，比较A-/T-和A+/T +受试者的eTAU、FDG和eAMY SUVR的判别能力。结果eTAU与FDG suv （r = 0.84, p < 0.001）、eTAU与eAMY suv （r > 0.87, p < 0.001）呈显著正相关。在个体水平上发现了与低代谢地形良好对应的显著灌注不足的群集，独立于潜在的神经退行性模式。eTAU和FDG suv对A+/T +和A-/T-个体有显著的区分（AUCeTAU=0.604， AUCFDG=0.748），其中FDG表现优于eTAU （p = 0.04）。eAMY和eTAU SUVR具有相当的判别能力。结论早期18F-Flortaucipir-PET可提供与早期淀粉样蛋白pet测量的脑区域糖代谢和灌注密切相关的灌注信息，尽管其作为神经变性生物标志物的准确性低于FDG-PET。
Early-phase 18F-Flortaucipir tau-PET as a proxy of brain metabolism in Alzheimer’s disease: a comparison with 18F-FDG-PET and early-phase amyloid-PET
Purpose
As dual-phase amyloid-PET can evaluate amyloid (A) and neurodegeneration (N) with a single tracer injection, dual-phase tau-PET might be able to provide both tau (T) and N. Our study aims to assess the association of early-phase tau-PET scans and 18F-fluorodeoxyglucose (FDG) PET and their comparability in discriminating Alzheimer’s disease (AD) patients and differentiating neurodegenerative patterns.
Methods
58 subjects evaluated at the Geneva Memory Center underwent dual-phase 18F-Flortaucipir-PET with early-phase acquisition (eTAU) and 18F-FDG-PET within 1 year. A subsample of 36 participants also underwent dual-phase amyloid-PET (eAMY). Standardized uptake value ratios (SUVRs) were calculated to assess the correlation of eTAU and their respective 18F-FDG-PET and eAMY scans. Hypometabolism and hypoperfusion maps and their spatial overlap were also evaluated at the individual level visually and semiquantitatively. Receiver operating characteristic analyses were performed to compare the discriminative power of eTAU, FDG, and eAMY SUVR between A-/T- and A+/T + participants.
Results
Strong positive correlations were found between eTAU and FDG SUVRs (r = 0.84, p < 0.001) and eTAU and eAMY SUVRs (r > 0.87, p < 0.001). Clusters of significant hypoperfusion with good correspondence to hypometabolism topographies were found at the individual level, independently of the underlying neurodegenerative patterns. Both eTAU and FDG SUVRs significantly distinguished A+/T + from A-/T- individuals (AUCeTAU=0.604, AUCFDG=0.748) with FDG performing better than eTAU (p = 0.04). eAMY and eTAU SUVR showed comparable discriminative power.
Conclusion
Early-phase 18F-Flortaucipir-PET can provide perfusion information closely related to brain regional glucose metabolism and perfusion measured by early-phase amyloid-PET, even if less accurate than FDG-PET as a biomarker for neurodegeneration.
期刊介绍：
The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
